-
Triastek Partners with Boehringer Ingelheim to Advance 3D Printed Drug Dosage Forms
•
China-based Triastek Inc., a leading pharmaceutical-focused 3D printing company, has entered into a partnership with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to explore the application of 3D printing in the development of new chemical entity (NCE) drug dosage forms, although no financial details were disclosed. Triastek’s Technology and…
-
ImmuneOnco Gains NMPA Approval for Phase Ib/II Study of IMM27M in Advanced Tumors
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase Ib/II clinical study for its IMM27M. This ADCC-enhanced CTLA-4 monoclonal antibody (mAb) will be combined with the programmed death-1 (PD-1) inhibitor tislelizumab for the treatment…
-
ArkBio and Calibr Renew Collaboration to Develop First-in-Class Respiratory Drug AK0705
•
Shanghai Ark Biopharmaceutical Co., Ltd announced that it has renewed its co-development collaboration with Calibr, a division of Scripps Research, to develop AK0705, a potential first-in-class drug targeting an enzyme that plays a crucial role in respiratory inflammation. The drug is intended to treat a broad spectrum of respiratory diseases,…
-
Agena Bioscience’s CYP2C19 Genotyping Kit Gains NMPA Approval for Cardiovascular Applications
•
Shanghai-based Agena Bioscience announced that its human CYP2C19 genotyping test kit, co-developed with Simcere Pharmaceutical Group’s subsidiary Simcere Diagnostics, has been approved by the National Medical Products Administration (NMPA) as a Category III product. The kit is designed for the qualitative detection of CYP2C19 gene polymorphism in peripheral blood samples…
-
Ping An Life Insurance Reports Steady Profit Growth and Expands Managed Care Services
•
Ping An Life Insurance Company of China Ltd released its 2022 financial report, recording RMB 148.365 billion (USD 21.485 billion) in operating profits, up 0.3% year-on-year (YOY). The company also reported RMB 107.432 billion (USD 15.55 billion) in net profits and RMB 83.774 billion (USD 12.13 billion) in net profits…
-
Akeso Biopharma Reports 422% Increase in Product Sales, Boosted by Cadonilimab and Penpulimab
•
China-based Akeso Biopharma (HKG: 9926) released its 2022 financial report, highlighting significant growth in product sales. The company reported RMB 1.104 billion (USD 159.97 million) in product sales, representing a 422% year-on-year (YOY) increase. Product Sales and Market ApprovalsThe innovative bispecific antibody cadonilimab (AK104), targeting programmed death-1 (PD-1) and cytotoxic…
-
CStone Pharmaceuticals Reports 97.54% Revenue Growth in 2022, Driven by Drug Sales and Licensing Fees
•
China-based CStone Pharmaceuticals (HKG: 2616) released its 2022 financial report, recording total revenues of RMB 481.4 million (USD 69.78 million), marking a 97.54% year-on-year (YOY) increase. This growth was primarily driven by drug sales and licensing fees for Cejemly (sugemalimab). Commercial revenues reached RMB 394.1 million (USD 57.1 million), up…
-
Henlius’ OX40 Monoclonal Antibody HLX51 Gains NMPA Approval for Phase I Clinical Study
•
Shanghai Henlius Biotech, Inc (HKG: 2696) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study in mainland China for its OX40 monoclonal antibody (mAb), HLX51. The study will focus on patients with advanced/metastatic solid tumors and lymphoma. Mechanism…
-
Boao Lecheng and Shanghai Biomed Center Form Long-Term Partnership for Medical Innovation
•
The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has entered into a long-term partnership with the Shanghai Center of Biomedicine Development. The collaboration will focus on various areas, including human genetic resources project management, international exchange and cooperation, translation of scientific and technological achievements, and enterprise innovation incubation…
-
Haisco Pharmaceutical’s EGFR-PROTAC HSK40118 Gains NMPA Approval for Clinical Trials
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its oral small molecule EGFR-PROTAC, HSK40118. The drug is targeted for the treatment of advanced non-small cell lung cancer (NSCLC). Drug Mechanism and Pre-Clinical ResultsHSK40118…
-
Astellas Pharma’s Xtandi Gains Momentum in China with Positive Phase III ARCHES Study Results
•
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that its prostate cancer therapy, Xtandi (enzalutamide), is poised to add a new indication for the China market following positive results from the Phase III China ARCHES study. The trial evaluated Xtandi in combination with androgen deprivation therapy (ADT) in men with…
-
World Orphan Drug Alliance Expands to China with RareStone Group Partnership
•
The World Orphan Drug Alliance (WODA) has announced its expansion to China for the first time, welcoming the addition of RareStone Group as a new member. RareStone Group is a China-based biopharma and patient platform focused on rare diseases. WODA is a global alliance of commercial distributors dedicated to providing…
-
MabPharm Files NDA for CMAB009, Biosimilar to Erbitux, Targeting Metastatic Colorectal Cancer
•
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the filing of a New Drug Application (NDA) for its CMAB009, a biosimilar of Merck KGaA (ETR: MRK)/Bristol-Myers Squibb’s (BMS, NYSE: BMY) cetuximab (trade name: Erbitux). The filing has been accepted for review by the National Medical Products…
-
Neowise Biotechnology Secures RMB 200 Million in Series A+ Financing Round
•
Neowise Biotechnology Co., Ltd, a T cell receptor (TCR)-therapy developer based in Suzhou, reportedly raised close to RMB 200 million (USD 29 million) in a Series A+ financing round. This investment will support the company’s ongoing research and development efforts in TCR therapies. Investor ParticipationThe financing round was led by…
-
Singde Yiyang Secures Series A Financing to Expand Wellness Services in China
•
Singde Yiyang, a leading wellness service provider based in Qingdao, reportedly raised “hundreds of millions” of renminbi in a Series A financing round led by Genertec Investment. The company plans to implement a “1+X+N” layout, covering key regions and cities in China, with a target of over 10,000 beds. Company…
-
Meinian Onehealth and Astra Biotechnology Partner on Hypersensitive Blood Biomarker Detection
•
China-based Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a partnership with compatriot firm Astra Biotechnology Co., Ltd to develop hypersensitive blood biomarker detection capabilities. The collaboration will focus on creating a humoral biomarker detection scheme and screening model for physical examinations targeting brain diseases and other…
-
Immorna Enrolls First Patient in Phase I Study of JCXH-211 for Malignant Tumors
•
Immorna (Hangzhou) Biotechnology, an mRNA-based vaccine developer based in Hangzhou, has announced the enrollment of the first patient in a Phase I clinical study to assess the safety and efficacy of JCXH-211, a potential cancer therapeutic, in malignant solid tumors in China. The study will determine the recommended Phase II…
-
XtalPi and DP Technology Partner to Accelerate Pre-Clinical Drug Development with AI
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a partnership with Beijing-based DP Technology. The collaboration aims to leverage DP Tech’s AI for Science computation platform and XtalPi’s intelligent, automatic drug research and development (R&D) solutions to streamline the pre-clinical drug R&D process, thereby accelerating drug development. XtalPi’s…
-
Laekna Therapeutics Files for IPO on Hong Kong Stock Exchange, Aims to Expand Cancer and Hepatic Fibrosis Therapies
•
China’s Laekna Therapeutics Shanghai Co., Ltd has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKSE), according to the exchange. The offering will be sponsored by CICC. This move marks a significant step in Laekna’s growth strategy as it seeks to raise capital to further…
-
LanssonPharm’s Anti-Depression Drug LS21031 Receives CDE Approval for Clinical Trials
•
China-based central nervous system (CNS) drug developer LanssonPharm has announced that it has received clinical trial approval from the Center for Drug Evaluation (CDE) for its anti-depression drug, LS21031. This PDE4 inhibitor is being developed to improve symptoms of depression and cognitive-related diseases. Mechanism of ActionLS21031 works by effectively inhibiting…
